Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature

Farris, Michael; Hughes, Ryan T.; Lamar, Zanetta S.; Soike, M.; Menke, Joshua; Ohgami, Robert S.; Winkfield, Karen M.

doi:10.1016/j.clml.2018.10.004

Cited by 7 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many reports have described the appearance of HS following or simultaneously with other neoplasias including solid tumors (breast, lung, colon) and hematologic malignancies, such as follicular lymphoma, myelodysplasia and acute lymphoblastic leukemia [14,15]. Thus HS can be classified as primary or secondary.…”

Section: Discussionmentioning

confidence: 99%

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Lage¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

Histiocytic Sarcoma (HS) is an uncommon malignancy derived from macrophage/dendritic lineage cells and accounts for less than 1% of hematologic tumors. Due to its rarity, little is known about its clinical-biological behavior and therapeutic recommendations have not been standardized so far. In addition to lymph node enlargement most cases present extranodal involvement, especially in the gastrointestinal tract, skin and soft tissues. Bone involvement is usually described in association with systemic disease and in advanced stages. Here we describe a case of patient with HS with primary bone involvement and multiple osteolytic lesions and bone fractures in the absence of another organs involvement. A male patient presented with an aggressive disease with rapid progression and his disease was unresponsive to standard therapy. Although rare, this kind of HS presentation should fall within the scope of differential diagnosis of other neoplasms with widespread bone involvement such as multiple myeloma and bone metastasis from solid tumors as the prostate, breast and lungs.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Lage¹

2019

Ann Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…There is currently no standard therapy for HS. Lymphoma‐type chemotherapies (CHOP, ABVD, Bendamustine) are widely used in a few retrospectives studies and case reports. A few studies describe the use of autologous or allogeneic haematopoietic stem cell transplantation as a first‐line therapy or as a therapy for relapsed or refractory disease, but have resulted in inconsistent outcomes …”

Section: Reviewmentioning

confidence: 99%

Targeted therapy of BRAF V600E‐mutant histiocytic sarcoma: A case report and review of the literature

Branco

Comont

Ysebaert

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

Bendamustine/rituximab

2019

Reactions Weekly

View full text Add to dashboard Cite

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature

Cited by 7 publications

References 46 publications

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Primary Histiocytic Sarcoma of Bone with Disseminated Involvement - Initial Presentation Mimicking Multiple Myeloma: The Atypical Face of a Rare Neoplasm

Targeted therapy of BRAF V600E‐mutant histiocytic sarcoma: A case report and review of the literature

Bendamustine/rituximab

Contact Info

Product

Resources

About